Coya Therapeutics — Third Quarter 2026 Earnings Summary

Coya Therapeutics completed enrollment of 137 participants in its Phase 2/3 ALSTARS trial for the treatment of ALS and announced plans for an open-label extension. The company reported a net loss of $10.6 million for the quarter ended September 30, 2026, driven primarily by a $5.6 million increase in clinical product candidate costs. As of September 30, 2026, Coya held $35.8 million in cash and cash equivalents, which is sufficient to fund operations through the second half of 2027. Topline data from the 24-week double-blind treatment phase of the ALSTARS trial is anticipated in early Q2 2027.